Clinical Trials on Focal Onset Seizure in Australia

Total 138 results

UCB Pharma

Completed

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Epilepsy

United States, Australia, Canada, Denmark, Germany, Italy, Poland, United Kingdom, Spain
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Sanofi

Completed

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Neoplasms | Neoplasm Metastasis | Neoplasm Recurrence, Local

Russian Federation, United States, Canada, Germany, Hungary, Italy, South Africa, Argentina, Uruguay, Austria, Switzerland, Israel, Belgium, France, Australia, Brazil, Greece, Guadeloupe, Réunion, Spain
BioMarin Pharmaceutical

Terminated

A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease

Late-onset Pompe Patients Untreated or Treated With rhGAA

Spain, Slovenia, Serbia, Korea, Republic of, Greece, Australia, Singapore, Brazil, Canada, Taiwan, Ireland, Poland, Romania
Engage Therapeutics, Inc.

Completed

Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern (StATES)

Epilepsy

Australia, United States, Jamaica
SK Life Science, Inc.

Recruiting

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Germany, Australia, Poland, Hungary
Marinus Pharmaceuticals

Withdrawn

To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Refractory Status Epilepticus

Spain, Switzerland, Germany, France, Austria, Italy, Belgium, United Kingdom, Czechia, Croatia, Finland, Lithuania, Israel, Hungary, Poland, Slovakia
GlaxoSmithKline
Bausch Health Americas, Inc.

Completed

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy (RESTORE2)

Seizures

Spain, Australia, Israel, Ukraine, Belgium, United States, South Africa, Hungary, United Kingdom, France, Germany, Poland, Russian Federation
Upsher-Smith Laboratories

Completed

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Epilepsy

Australia, Canada, Poland, United States, Belgium, Spain, Argentina, Israel, India, South Africa, Greece, Russian Federation, Chile, New Zealand, Germany
Upsher-Smith Laboratories

Completed

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Epilepsy

United States, Australia, Poland, Belgium, Spain, Argentina, Israel, India, South Africa, Greece, Russian Federation, Chile, Germany, New Zealand, Hungary, Canada
Bristol-Myers Squibb

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

Alzheimer Disease, Early Onset

United States, Australia, Belgium, Canada, Denmark, France, Japan, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Sweden, United Kingdom
UCB BIOSCIENCES, Inc.
UCB Biopharma SRL

Completed

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Estonia, France, Georgia, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Moldova, Republic of, Monten... and more
UCB Pharma

Completed

Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures

Epilepsy

United States, Argentina, Australia, Belgium, Bulgaria, Colombia, Croatia, Czechia, Estonia, Georgia, Hungary, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Montenegro, Poland, Romania, Russian Federation, Serbia, Sl... and more
UCB Biopharma S.P.R.L.

Terminated

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Epilepsy

United States, Australia, Hungary, Israel, Poland, Ukraine, Spain, Canada, Germany, New Zealand
SK Life Science, Inc.

Completed

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

Australia, United States, Korea, Republic of, Germany, Hungary, Serbia, Bulgaria, Czechia, France, Israel, Poland, Romania, Spain, Thailand, Ukraine
UCB Biopharma S.P.R.L.

Terminated

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (ARTEMIS1)

Epilepsy

United States, Australia, Canada, Germany, Hungary, Israel, Italy, New Zealand, Poland, Spain, Ukraine
Chinook Therapeutics U.S., Inc.

Active, not recruiting

Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

Diabetic Kidney Disease | Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | IgA Nephropathy | Diabetic Nephropathy Type 2 | Alport Syndrome

United States, Spain, Korea, Republic of, Australia, Italy, United Kingdom
Sage Therapeutics

Completed

A Study With SAGE-547 for Super-Refractory Status Epilepticus

Super-Refractory Status Epilepticus

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Serbia, Spain, Sweden, United Kingdom
UCB Pharma

Completed

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures (BRITE)

Epilepsy

United States, Czechia, Germany, Poland, Austria, Belgium, Brazil, Bulgaria, Canada, Estonia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Puerto Rico, Russian Federation and more
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
Amicus Therapeutics

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Pompe Disease (Late-onset)

United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
SK Life Science, Inc.

Completed

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Partial Epilepsy

United States, Spain, Korea, Republic of, Serbia, Germany, Bulgaria, Argentina, Australia, Chile, Czechia, Hungary, Mexico, Poland, Russian Federation, Sweden, Thailand, Ukraine
Janssen Research & Development, LLC

Completed

A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

Erythroblastosis, Fetal | Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)

United States, Canada, Netherlands, Belgium, Australia, Germany, Spain, Sweden, United Kingdom
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
Amicus Therapeutics

Terminated

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Late-onset Pompe Disease

United States, Canada, Australia, Belgium
Novartis Pharmaceuticals

Completed

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)

Cryopyrin-associated Periodic Syndromes (CAPS) | Familial Cold Autoinflam Syn (FCAS) | Muckle-wells Syn (MWS) | Neonatal Onset Multisystem Inflam Disease (NOMID)

Switzerland, United States, Germany, Norway, Austria
Novartis Pharmaceuticals

Completed

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)

Tuberous Sclerosis Complex-associated Refractory Seizures

United States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
SK Life Science, Inc.

Recruiting

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

Primary Generalized Epilepsy

United States, Spain, Germany, Hungary, Korea, Republic of, Australia, Bulgaria, Czechia, Poland, Slovakia, Ukraine
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
Lundbeck LLC

Completed

Clobazam in Patients With Lennox-Gastaut Syndrome

Epilepsy | Epilepsy, Generalized | Seizures

United States, Belarus, India, Australia, Lithuania
University Hospital Plymouth NHS Trust
University of Plymouth

Completed

Recurrence After Whipple's (RAW) Study

Pancreatic Cancer | Surgery | Bile Duct Cancer | Pancreatic Ductal Adenocarcinoma | Survivorship | Cholangiocarcinoma, Extrahepatic | Cancer Recurrence | Recurrent Cancer | Pancreatic Ductal Carcinoma | Cholangiocarcinoma of the Extrahepatic Bile Duct | Ampullary Cancer | Cholangiocarcinoma Resectable | Cancer... and other conditions

Spain, United Kingdom, Australia, Austria, Italy, Mexico, Sudan, Pakistan
SK Life Science, Inc.

Recruiting

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

Seizures | Lennox Gastaut Syndrome

United States, Korea, Republic of, Taiwan, Colombia, Australia, Poland, Serbia, Mexico, Spain, Greece, Italy, Portugal, Germany, Argentina, Israel
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide (UPWARD)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

France, Germany, Spain, United States, Argentina, Australia, Belgium, Canada, Chile, Czechia, Finland, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Singapore, Sweden, Taiwan, United Kingdom
Genzyme, a Sanofi Company

Completed

Late-Onset Treatment Study Extension Protocol

Glycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)

United States, France, Canada, Netherlands, Australia
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Light Sciences Oncology

Completed

Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases

Neoplasm Metastasis | Colorectal Neoplasms | Liver Metastases | Neoplasm Recurrence, Local

Sweden, India, Austria, Serbia, Germany, Romania, Croatia, Bosnia and Herzegovina, Italy, Latvia, Poland, Russian Federation, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Tuberous Sclerosis Complex

United States, Spain, Belgium, Taiwan, Turkey, Australia, Korea, Republic of, Thailand, France, Hungary, United Kingdom, Italy, Japan, Canada, Russian Federation, Poland, Mexico, Colombia
Jazz Pharmaceuticals

Completed

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Seizures | Tuberous Sclerosis Complex

United States, Spain, Australia, Poland, United Kingdom, Netherlands

Clinical Trials on Focal Onset Seizure in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations